000			02026 a2200541 4500
005			20250513184052.0
264		0	_c19990803
008			199908s 0 0 eng d
022			_a1046-6673
024	7		_a10.1681/ASN.V1061331 _2doi
040			_aNLM _beng _cNLM
100	1		_avan der Pijl, J W
245	0	0	_aEffect of danaparoid sodium on proteinuria, von Willebrand factor, and hard exudates in patients with diabetes mellitus type 2. _h[electronic resource]
260			_bJournal of the American Society of Nephrology : JASN _cJun 1999
300			_a1331-6 p. _bdigital
500			_aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAnalysis of Variance
650	0	4	_aAnticoagulants _xadministration & dosage
650	0	4	_aChondroitin Sulfates _xadministration & dosage
650	0	4	_aDermatan Sulfate _xadministration & dosage
650	0	4	_aDiabetes Mellitus, Type 2 _xdrug therapy
650	0	4	_aDiabetic Nephropathies _xdrug therapy
650	0	4	_aDiabetic Retinopathy _xdrug therapy
650	0	4	_aDouble-Blind Method
650	0	4	_aDrug Combinations
650	0	4	_aEndothelium, Vascular _xmetabolism
650	0	4	_aExudates and Transudates _xdrug effects
650	0	4	_aFemale
650	0	4	_aFollow-Up Studies
650	0	4	_aHeparitin Sulfate _xadministration & dosage
650	0	4	_aHumans
650	0	4	_aKidney Function Tests
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aProteinuria _xdrug therapy
650	0	4	_aReference Values
650	0	4	_aStatistics, Nonparametric
650	0	4	_avon Willebrand Factor _xdrug effects
700	1		_aLemkes, H H
700	1		_aFrölich, M
700	1		_avan der Woude, F J
700	1		_avan der Meer, F J
700	1		_aVan Es, L A
773	0		_tJournal of the American Society of Nephrology : JASN _gvol. 10 _gno. 6 _gp. 1331-6
856	4	0	_uhttps://doi.org/10.1681/ASN.V1061331 _zAvailable from publisher's website
999			_c10320448 _d10320448